Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? - Wikidata - awgldk - TriplyDB

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?

http://www.wikidata.org/entity/Q28075208

about

Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B.Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus

P2860

Q38376533-8C33040C-A61E-498D-AA29-DCDDD3ACAB9B Q39006152-30FDA54D-8E0C-40D5-8DED-13C4A7EA9FAE Q45873262-FDDEA4C3-5104-47D7-9800-3B0DCF03A12C Q47191156-D28C0949-3F36-40AF-AB25-8CA909A59E81 Q58718580-1FB21346-CE94-4747-B159-DECD34D1420D

P2860

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?

http://www.wikidata.org/entity/Q28075208

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Individualized prophylaxis for ...... eloped and developing nations?

@ast

Individualized prophylaxis for ...... eloped and developing nations?

@en

Individualized prophylaxis for ...... eloped and developing nations?

@nl

type

label

Individualized prophylaxis for ...... eloped and developing nations?

@ast

Individualized prophylaxis for ...... eloped and developing nations?

@en

Individualized prophylaxis for ...... eloped and developing nations?

@nl

prefLabel

Individualized prophylaxis for ...... eloped and developing nations?

@ast

Individualized prophylaxis for ...... eloped and developing nations?

@en

Individualized prophylaxis for ...... eloped and developing nations?

@nl

P1433

Q28075208-F1C1363C-199F-46BA-9996-725279D5B294

P1476

Q28075208-C94B802C-6C4C-44A5-AE5F-055339406A01

P2093

Q28075208-8E69A796-A2AF-4CCE-A0EB-ED0A77555704

Q28075208-C849C0AE-39B3-46E2-85AF-198C83884550

P2860

Q28075208-08E100D4-2FF3-4BB5-9398-3AE0657F1A6D

Q28075208-0F28E493-ECB3-4219-B005-E57EE7DEEE56

Q28075208-1ADC48BE-7737-4AD5-ABFB-27664550FD2C

Q28075208-1E2160A5-3DD8-43C1-83A0-77392EFAD7C3

Q28075208-4192E290-17BA-44B5-984E-7D1112A01773

Q28075208-46BE5234-8E87-45EE-A01E-49FF5B5FB52A

Q28075208-5D99B3FD-CA2C-4110-8303-34DC5D01B4DF

Q28075208-7D129488-E2E4-46CD-AFF8-A4D170EDC5F9

Q28075208-85753EDA-0AB6-443D-9D22-77600F07D533

Q28075208-8AB0179E-C1CC-4FEC-AA4B-0D1FC8F0D619

P2888

Q28075208-62413AB6-95AC-4F84-8340-8BA67DF7A05F

P304

Q28075208-9C536C9E-44DC-4AE6-8CAD-0AED41233DA3

P31

Q28075208-827520B2-625B-45AE-BDB8-179A6C5DFAFC

P3181

Q28075208-F9FBADF2-E11E-4E9D-887A-C3E901FB89E7

P356

Q28075208-0BF766D4-0893-4A24-B117-337DE5569095

P407

Q28075208-0A891818-6C92-4E96-981E-FEA744F74BC2

P433

Q28075208-C8849F55-9A8B-42EA-AC4F-90BCA917BFC1

P478

Q28075208-906A2417-5078-45A7-B143-D8C8074C2FB5

P577

Q28075208-CE2D3C4B-2C50-4249-B1B8-EAD5BC559CEE

P6179

Q28075208-6EBAFC79-3D4C-4A91-8197-1A91B9A14F64

P698

Q28075208-2A7A609D-CDFA-4E58-ACB9-B35064A9A6B0

P921

Q28075208-F1C40CC9-1352-47FB-B933-A43A0487C09B

P932

Q28075208-899CFD20-2C95-4D3D-88C9-453F16EEFC7C

P3181

P356

S12959-016-0096-Y

P1433

Thrombosis journal

P1476

Individualized prophylaxis for ...... eloped and developing nations?

@en

P2093

Adrienne Lee

http://www.w3.org/2001/XMLSchema#string

Man-Chiu Poon

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.

The burden of bleeding in haemophilia: is one bleed too many?

Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).

Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres.

P2888

s12959-016-0096-y

P304

32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3147366

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12959-016-0096-Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044335908

http://www.w3.org/2001/XMLSchema#string

P698

27766058

http://www.w3.org/2001/XMLSchema#string

P921

P932

5056486

http://www.w3.org/2001/XMLSchema#string